TABLE 1.
Basic characteristics of participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study, Alzheimer's Disease Neuroimaging Initiative (ADNI), and the Busselton Health Study (BHS)
| AIBL | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number of APOE ε2 alleles | Number of APOE ε4 alleles | |||||||
| 0 | 1 | 2 | P value | 0 | 1 | 2 | P‐value | |
| N | 564 | 124 | 5 | 520 | 163 | 10 | ||
| Age (years) | 75.2 (6.5) | 75.5 (6.9) | 75.4 (5.2) | .927 | 75.7 (6.7) | 74.2 (5.8) | 71.6 (6.2) | .01 |
| Gender (% female) | 327 (58.0) | 77 (62.1) | 4 (80.0) | .44 | 303 (58.3) | 100 (61.3) | 5 (50.0) | .665 |
| BMI (kg/m2) | 26.30(4.4) | 26.3 (4.4) | 25.6 (5.1) | .927 | 26.3 (4.2) | 26.3 (4.8) | 26.6 (4.2) | .966 |
| HDL‐C (mmol/L) | 1.56 (0.41) | 1.67 (0.47) | 1.58 (0.54) | .029 | 1.58 (0.43) | 1.56 (0.42) | 1.68 (0.46) | .656 |
| Total Cholesterol (mmol/L) | 5.28 (1.12) | 5.15 (1.05) | 5.52 (2.41) | .444 | 5.23 (1.11) | 5.35 (1.16) | 5.51 (0.94) | .4 |
| Triglycerides (mmol/L) | 1.27 (0.61) | 1.19 (0.54) | 2.30 (2.42) | .001 | 1.25 (0.63) | 1.32 (0.65) | 1.15 (0.46) | .4 |
| 1 | 37 (6.6) | 8 (6.5) | 0 (0.0) | 38 (7.3) | 7 (4.3) | 0 (0.0) | ||
| 2 | 57 (10.1) | 15 (12.1) | 1 (20.0) | 55 (10.6) | 17 (10.4) | 1 (10.0) | ||
| 3 | 28 (5.0) | 5 (4.0) | 0 (0.0) | 23 (4.4) | 10 (6.1) | 0 (0.0) | ||
| 4 | 63 (11.2) | 9 (7.3) | 0 (0.0) | 53 (10.2) | 17 (10.4) | 2 (20.0) | ||
| 5 | 379 (67.2) | 87 (70.2) | 4 (80.0) | 351 (67.5) | 112 (68.7) | 7 (70.0) | ||
| ADNI | ||||||||
|---|---|---|---|---|---|---|---|---|
| N | 174 | 31 | 2 | 152 | 50 | 5 | ||
| Age (years) | 75.8 (4.8) | 75.2 (5.6) | 73.5 (4.7) | .661 | 75.7 (5.0) | 76.0 (5.0) | 74.6 (3.8) | .812 |
| Gender (%female) | 82 (47.1) | 19 (61.3) | 0 (0.0) | .133 | 76 (50.0) | 23 (46.0) | 2 (40.0) | .819 |
| BMI (kg/m2) | 26.8 (4.4) | 26.5 (4.0) | 28.5 (1.2) | .782 | 27.2 (4.5) | 25.8 (3.9) | 24.8 (2.3) | .087 |
| HDL‐C (mmol/L) | 1.36 (0.43) | 1.43 (0.58) | 1.32 (0.44) | .73 | 1.39 (0.44) | 1.35 (0.49) | 1.24 (0.44) | .693 |
| Cholesterol (mmol/L) | 4.74 (0.93) | 4.76 (0.95) | 3.37 (1.23) | .119 | 4.72 (0.94) | 4.81 (0.96) | 4.37 (0.66) | .566 |
| Triglycerides (mmol/L) | 1.42 (0.76) | 1.54 (1.06) | 0.93 (0.54) | .516 | 1.37 (0.68) | 1.61 (1.11) | 1.36 (0.64) | .19 |
| Fasting status (% fasting) | 16 (9.2) | 3 (9.7) | 0 (0.0) | .9 | 17 (11.2) | 0 (0.0) | 2 (40.0) | .003 |
| BHS | ||||||||
|---|---|---|---|---|---|---|---|---|
| N | 3625 | 733 | 26 | 3221 | 1061 | 102 | ||
| Age (years) | 50.4 (17.3) | 50.7 (17.6) | 50.7 (16.7) | .9 | 50.67 (17.5) | 50.2 (17.0) | 47.9 (17.0) | .228 |
| Gender (% female) | 2032 (56.1) | 413 (56.3) | 16 (61.5) | .848 | 1836 (57.0) | 572 (53.9) | 53 (52.0) | .147 |
| BMI (kg/m2) | 26.0 (4.2) | 26.1 (4.2) | 25.6 (4.3) | .844 | 26.0 (4.2) | 26.0 (4.2) | 25.4 (4.0) | .315 |
| HDL‐C (mmol/L) | 1.38 (0.39) | 1.44 (0.41) | 1.45 (0.40) | .001 | 1.40 (0.39) | 1.37 (0.40) | 1.32 (0.37) | .024 |
| Cholesterol (mmol/L) | 5.65 (1.10) | 5.26 (1.10) | 4.37 (1.14) | <.001 | 5.52 (1.12) | 5.74 (1.08) | 5.65 (1.09) | <.001 |
| Triglycerides(mmol/L) | 1.29 (0.91) | 1.34 (0.90) | 1.38 (1.01) | .43 | 1.28 (0.89) | 1.38 (0.91) | 1.33 (1.25) | .009 |
*
In this study, we only used the records at the last time point in AIBL cohort.